DA4 Buprenorphine and Buprenorphine Naloxone combination Suboxone prescribing guidance


Category
Drug and Alcohol
Code
DA4
Issue No
1

Target Audience

Medical Officers and Substance Misuse Practitioners within drug treatment services and general practices involved in shared care of problem drug users.

Purpose

To ensure flexible, safe and consistent prescribing practice across drug treatment services.

Origin

Lead executive
Lead Clinical Director

Author and contact number
Clinical Directors, D&A Services
0151 604 7309


Policy dates & history

Implementation Date

16 October 2012

Review Date

31 October 2017

Approval Meeting

Medicines Management Group (MMG)

Ratification

Document Quality Group (DQG)

Download

DA4 Buprenorphine and Buprenorphine Naloxone combination Suboxone prescribing guidance Issue 1.pdf

0.07MB
Download Now
Text size A- A+
Contrast options